Member Info for Reserved

I am invested in both Destiny and Ondine.

There is regular and positive communication from Ondine, although a commercial breakthrough has yet to be achieved. A similar approach to the provision of information by Destiny would be helpful.

Very positive endorsements.

This must bode well for commercialisation in the next 12 months.

Buys going through as sells.

Wgumcd

You made reference to Steriwave being 50% effective, but the following extract from Edison states:

"In Q422, the company reported that its US Phase II nasal disinfection study met the primary endpoint of eliminating or significantly decreasing nasal Staphylococcus aureus in 86% of carriers. "

Here is the link to the article: https://www.edisongroup.com/research/steriwave-initiates-uk-pilot-study-with-nhs/32588/

Peterobert - I agree

For anyone wanting to listen to the 2 minute video by Prof Claire Hopkins here is the link

https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68

Peterobert

You beat me to it. Sorry for duplicating the information

I received the following information from Ondine following the release of the RNS:

"We are very pleased as this procurement authorization facilitates the ability for HCA clinicians across the HCA UK network to adopt Steriwave to prevent healthcare-associated infections for their patients and reduce unnecessary antibiotic use. HCA UK has built a world-class network of over 30 facilities in London and Manchester, with its latest venture opened in Birmingham in 2023. HCA is the largest private healthcare provider in the world and one of the leading private healthcare providers in the UK. HCA Healthcare UK, is the only private hospital group in the UK to have the highest level of critical care beds in all of its facilities, and it positively takes on new challenges in innovation and advancing critical care. We believe our clinical work to advance the use of Steriwave into ICUs will be leveraged by this key procurement relationship in due course.

The procurement clearance at HCA UK, following the recent news of our first NHS hospital deployments in Mid Yorkshire, we believe bodes well for our growth goals."

Whilst I agree pricing details would be useful to fully consider the value of the company, I believe they are making steady progress and their relationship with HCA appears strong and could provide the opportunity for significant growth in the US. An update on progress of the Phase 3 trial is awaited with interest.

Thanks for the words of welcome. I hope I can bring something to the group. There are certainly some usefule observations and thoughts.

The link to Investors' Chronicle, which gives a target price of 64p, is:

https://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=ENET:LSE

Mickey -Thanks for the welcome. I wish I could exercise "good judgement" every time the need for a decision arises.

I am exercising "control" at the moment despite the very positive view of the analyst referred to at Investors' Chronicle.

The last RNS is a business update. I believe it is positive, but there is nothing definite. Here is a list of caveats that are used.

positive engagement

a number of potential new customers

indicated an interest

potential contracts

could lead to significant business

should they lead to contracts

could contribute

would likely lead to significantly higher revenues

Whilst there can be no guarantee

potential for future growth in sales

Andoman99

The 75,000 sold at 4.349 is a buy.

Observations:

JP Errico resingned from electroCore Board in May 2023.

Joined Ondine in January 2024.

LinkedIn profile (Experience) does not mention Ondine

Although the following article relates to rare earths, it is interesting to note the measures that governments may adopt to protect access to resources.

"Japanese Template

...... Back in 2010, China threatened to cut off supplies of rare earths to Japan, threatening the viability of Japanese companies producing advanced technical equipment and forcing Japan to mount a rescue bid for a financially stressed miner, Lynas Rare Earths, by offering capital to complete mine development and a contract to supply future rare earths.

That rescue of the Mt Weld mine of Lynas led to the creation of the biggest rare earth business outside China......."

Link to full article: https://www.forbes.com/sites/timtreadgold/2024/03/12/nickel-rescue-plan-risks-starting-a-new-trade-war/?sh=6777846832e5

Steve305 - I think we should avoid trying to guess the reasons for a resignation. Personally, I believe we should consider the overall situation: the developments re the NHS trials, the progress towards the FDA phase 3 trial and the ramping up of production capability are worthy of a positive outlook.

Nofear52 - I don't think the SP is aligned with the points you have noted.

Proactive Investors interview:

"The company aims to develop a business case with York health economics group and Mid Yorkshire for broader NHS adoption, based on the successful outcomes and health economics work."

There are 195 NHS trusts, excluding Ambulance and Mental Health trusts, many with more than one site. If Steriwave is widely adopted after the preparation of the business case, the potential number of applications is considerable. There are also private hospitals to consider.

This extract is from the Ondine news update 25/03/24:

"SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care – the antibiotic mupirocin – less effective."

There is a massive opportunity for Ondine IMO.

The 3 sell trades at 10p just before the close were my buys. Can someone explain how I was offered a price so different to the other buys that occurred around the same time.

If you are wondering why I made 3 trades: after the first trade, I decided it was worth buying more and then just before the close, I wondered if I could repeat my good fortune and since I could, I bought some more.

RNS 13/12/23

"The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology."

Let's hope their discussions with all 75 hospitals are successful.

In terms of cash runway the RNS on 11/12/23 stated:

"The net proceeds from the Fundraising will provide further cash runway until at least mid Q2 2024. The Company continues to evaluate funding opportunities for its Phase 3 study in the US, subject to the finalisation of the trial design with the FDA, and for further commercial development internationally."

Question: will another fundraise be required?

Well, that is a perfect answer to the question I raised yesterday about the Pontefract trial.

Sisyphus - thank you for your response.